NCT02541604 · OUTCOME

DOR as Determined by the Investigator Using irRC for Participants With Neuroblastoma

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors · Source last updated 2020-02-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

Analysis population: Included safety-evaluable population, defined as patients who received any amount of study drug. No participants had response therefore no participants analyzed.

Groups in this outcome

Cohort 3

Participants with neuroblastoma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Cohort 3	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

groups

description
Participants with neuroblastoma
id
OG000
title
Cohort 3

population Description

Included safety-evaluable population, defined as patients who received any amount of study drug. No participants had response therefore no participants analyzed.

reporting Status

POSTED

time Frame

Baseline until disease progression, or death from any cause, whichever occurs first (up to approximately 42 months)

title

DOR as Determined by the Investigator Using irRC for Participants With Neuroblastoma

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice